



## VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019

February 5, 2019

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that [Shawn Singh, Chief Executive Officer of VistaGen](#), will present at the 21<sup>st</sup> Annual [BIO CEO & Investor Conference](#) to be held February 11-12, 2019 at the New York Marriott Marquis in New York City. The Company's presentation will be on Monday, February 11, 2019 at 1:45 p.m. EST.

For more information regarding the conference or to schedule a one-on-one meeting with VistaGen's management team, please contact KCSA Strategic Communications via email: [VistaGen@KCSA.com](mailto:VistaGen@KCSA.com), your BIO CEO representative via email: [biopartnering@bio.org](mailto:biopartnering@bio.org), or visit the conference website: <https://www.bio.org/events/bio-ceo-investor-conference/contact>.

### About VistaGen

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. Each of VistaGen's CNS pipeline candidates, AV-101, PH10 and PH94B, has potential to provide rapid-onset therapeutic benefits without the psychological and other side effects, safety concerns or inconvenient clinical administration associated with many current and potential new generation medications for CNS diseases and disorders, such as major depressive disorder (MDD) and social anxiety disorder (SAD). Each drug candidate in VistaGen's pipeline is either currently in or has completed Phase 2 clinical development. AV-101, an oral NMDA receptor glycine B antagonist, is in Phase 2 development, initially as an adjunctive treatment of MDD. The FDA has granted Fast Track designation for development of AV-101 as both a potential [adjunctive treatment of MDD](#) and as a [non-opioid treatment for neuropathic pain](#). PH10 intranasal, a first-in-class neuroactive steroid with rapid onset effects, is in Phase 2 development for MDD. PH94B intranasal, also a first-in-class neuroactive steroid with rapid onset effects, has completed Phase 2 development and is now being prepared for pivotal Phase 3 clinical development as an on-demand PRN treatment of SAD.

For more information, please visit [www.vistagen.com](http://www.vistagen.com) and connect with VistaGen on [Twitter](#), [LinkedIn](#) and [Facebook](#).

### Company Contact

Mark A. McPartland  
VistaGen Therapeutics Inc.  
Phone: +1 (650) 577-3600  
Email: [IR@vistagen.com](mailto:IR@vistagen.com)

### Investor Contact

Valter Pinto / Allison Soss  
KCSA Strategic Communications  
Phone: +1 (212) 896-1254/+1 (212) 896-1267  
Email: [VistaGen@KCSA.com](mailto:VistaGen@KCSA.com)

### Media Contact

Caitlin Kasunich / Lisa Lipson  
KCSA Strategic Communications  
Phone: +1 (212) 896-1241/+1 (508) 843-6428  
Email: [VistaGen@KCSA.com](mailto:VistaGen@KCSA.com)



VistaGen®  
Therapeutics

Source: VistaGen Therapeutics, Inc.

Released February 5, 2019